Data as of Q4 2025 (Dec 31, 2025)

RA CAPITAL MANAGEMENT, L.P.

โ€ขCIK: 1346824โ€ขFiling: Q4 2025

RA Capital Management, L.P., led by renowned investor Raoul de Vitry d'Avaucourt, is known for its concentrated, high-conviction bets, currently holding 71 positions with a focus on biotech and healthcare. The fund has recently made notable moves by adding BCRX, PRAX, and OLMA, while exiting ETNBGBP and SRRK, and significantly increasing stakes in JBIO and DSGN, reflecting its aggressive growth strategy.

Total AUM
$9.8B
QoQ Performance
+20.3%
Positions
71
Top 10 Concentration
65.6%
Latest Filing
Q4 2025

Top Holdings Allocation

ASND
CDTX
RYTM
RNAGBP
PCVX
ASND22.5%
CDTX7.6%
RYTM7.3%
RNAGBP6.4%
PCVX5.1%
SION4.2%
NAMS3.4%
TYRA3.3%

๐Ÿ“ˆ Biggest Buys

BCRX
BIOCRYST PHARMACEUTICALS INC
NEW
1.3% of portfolio
PRAX
PRAXIS PRECISION MEDICINES I
NEW
1.1% of portfolio
RYTM
RHYTHM PHARMACEUTICALS INC
+17.3%
7.3% of portfolio
OLMA
OLEMA PHARMACEUTICALS INC
NEW
0.7% of portfolio
NUVL
NUVALENT INC-A
+50.8%
1.9% of portfolio

๐Ÿ“‰ Biggest Sells

CLYM
CLIMB BIO INC
-64.1%
0.8% of portfolio
ACLX
ARCELLX INC
-58.3%
0.8% of portfolio
BLTE
BELITE BIO INC - ADR
-50.6%
0.7% of portfolio
PCVX
VAXCYTE INC
-10.4%
5.1% of portfolio
DNTH
DIANTHUS THERAPEUTICS INC
-43.8%
0.7% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

ETNBGBP
89BIO INC
SOLD
$292.4M
SRRK
SCHOLAR ROCK HOLDING CORP
SOLD
$43.5M
GPCR
STRUCTURE THERAPEUTICS INC
SOLD
$42.5M
โ€”
METSERA INC
SOLD
$35.4M
TVTX
TRAVERE THERAPEUTICS INC
SOLD
$27.5M
+13 more exited positions

Changes from Q3 2025

NEW22 new positions
โ†‘13 increased
โ†“8 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023